Pharmacological inhibition of Kv3 on oxidative stress-induced cataract progression

Biochem Biophys Res Commun. 2020 Dec 17;533(4):1255-1261. doi: 10.1016/j.bbrc.2020.09.138. Epub 2020 Oct 14.

Abstract

Oxidative stress is one of the most important risk factors for cataractogenesis. Previous studies have indicated that BDS-II, a Kv3 channel blocker, plays pivotal roles in oxidative stress-related diseases. This study demonstrates that BDS-II exerts a protective effect on cataractogenesis. Specifically, BDS-II was observed to inhibit lens opacity induced by H2O2. BDS-II was also determined to inhibit cataract progression in a sodium selenite-induced in vivo cataract model by inhibiting reduction of the total GSH. In addition, BDS-II was demonstrated to protect human lens epithelial cells against H2O2-induced cell death. Our results suggest that BDS-II is a potential pharmacological candidate in cataract therapy.

Keywords: BDS-II; Cataract; Cataractogenesis; Kv3; Oxidative stress.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cataract / prevention & control*
  • Cell Death
  • Cell Line
  • Disease Progression
  • Epithelial Cells / drug effects
  • Female
  • Humans
  • Lens, Crystalline / cytology
  • Male
  • Oxidative Stress / drug effects*
  • Potassium Channel Blockers / pharmacology
  • Potassium Channel Blockers / therapeutic use*
  • Rats, Sprague-Dawley
  • Shaw Potassium Channels / antagonists & inhibitors*
  • Shaw Potassium Channels / metabolism

Substances

  • Potassium Channel Blockers
  • Shaw Potassium Channels